APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application

Targeting CD40 with agonist antibodies is a promising approach to cancer immunotherapy. CD40 acts as a master regulator of immunity by mobilizing multiple arms of the immune system to initiate highly effective CD8 + T-cell-mediated responses against foreign pathogens and tumors. The clinical develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Filbert, Erin L., Björck, Pia K., Srivastava, Minu K., Bahjat, Frances R., Yang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195934/
https://www.ncbi.nlm.nih.gov/pubmed/33392713
http://dx.doi.org/10.1007/s00262-020-02814-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195934/
https://www.ncbi.nlm.nih.gov/pubmed/33392713
http://dx.doi.org/10.1007/s00262-020-02814-2

Ejemplares similares